Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878149 | 0.81 | LMNA (0.41) | POLBLMNANPC1RAB9ACYP1A2 | |
| SCHEMBL3618067 | 0.81 | LMNA (0.46) | POLBLMNARAB9ANR3C1SMN1; SMN2 | |
| SCHEMBL3610695 | 0.81 | NR1H4 (0.50) | POLBLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3616979 | 0.79 | NAMPT (0.47) | POLBLMNANPC1RAB9ATSHR | |
| SCHEMBL14066581 | 0.78 | MAPT (0.59) | POLBSMN1; SMN2ALDH1A1GAAMAPT | |
| SCHEMBL4710501 | 0.77 | RAB9A (0.42) | LMNANPC1RAB9ACYP1A2CYP2D6 | |
| SCHEMBL4882648 | 0.77 | F10 (0.43) | POLBLMNANPC1RAB9ACYP1A2 | |
| SCHEMBL3618727 | 0.77 | LMNA (0.41) | POLBLMNANPC1RAB9ATSHR | |
| SCHEMBL14066578 | 0.77 | F10 (0.43) | POLBLMNANPC1RAB9ACYP1A2 | |
| SCHEMBL3621276 | 0.76 | NPC1 (0.44) | NPC1RAB9ATSHRSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
| EP-1819701-A1 | CYCLIC IMINOCARBAMATES AND USE THEREOF | Bayer HealthCare AG (DE) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006058630-A1 | CYCLIC IMINOCARBAMATES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | F2, UQCRB, F12 | POLB 433/4885LMNA 66/4885NPC1 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.